We are live on ! Find out more
DCPH

Deciphera Pharmaceuticals, Inc. Common Stock

Delisted

DCPH was delisted on the 10th of June, 2024.

78 hedge funds and large institutions have $460M invested in Deciphera Pharmaceuticals, Inc. Common Stock in 2018 Q4 according to their latest regulatory filings, with 15 funds opening new positions, 31 increasing their positions, 19 reducing their positions, and 25 closing their positions.

New
Increased
Maintained
Reduced
Closed

63% more repeat investments, than reductions

Existing positions increased: 31 | Existing positions reduced: 19

11% less funds holding

Funds holding: 8878 (-10)

25% less funds holding in top 10

Funds holding in top 10: 43 (-1)

40% less first-time investments, than exits

New positions opened: 15 | Existing positions closed: 25

44% less capital invested

Capital invested by funds: $822M → $460M (-$363M)

Holders
78
Holders Change
-10
Holders Change %
-11.36%
% of All Funds
1.74%
Holding in Top 10
3
Holding in Top 10 Change
-1
Holding in Top 10 Change %
-25%
% of All Funds
0.07%
New
15
Increased
31
Reduced
19
Closed
25
Calls
$243K
Puts
Net Calls
+$243K
Net Calls Change
-$109K
Name Holding Trade Value Shares
Change
Change in
Stake
Fidelity Investments
26
Fidelity Investments
Massachusetts
$3.1M -$19.4M -791,006 -84%
Northern Trust
27
Northern Trust
Illinois
$2.92M -$28.9K -1,175 -0.8%
FI
28
Fosun International
China
$2.69M
Axa
29
Axa
France
$2.64M
NC
30
Nexthera Capital
New York
$2.56M +$2.24M +91,270 +298%
SFM
31
Sphera Funds Management
Israel
$2.42M +$123K +5,000 +5%
Deutsche Bank
32
Deutsche Bank
Germany
$2.04M -$1.12M -45,745 -32%
SA
33
Sunesis Advisors
Kansas
$2.02M
Alyeska Investment Group
34
Alyeska Investment Group
Illinois
$1.95M -$1.19M -48,607 -34%
Citigroup
35
Citigroup
New York
$1.54M +$1.2M +48,850 +197%
EP
36
Eversept Partners
New York
$1.46M +$1.71M +69,700 New
Charles Schwab
37
Charles Schwab
California
$1.46M -$27.5K -1,120 -2%
UBS Group
38
UBS Group
Switzerland
$1.03M +$1.08M +43,892 +842%
Bank of New York Mellon
39
Bank of New York Mellon
New York
$981K -$484K -19,704 -30%
Morgan Stanley
40
Morgan Stanley
New York
$904K +$696K +28,295 +191%
Goldman Sachs
41
Goldman Sachs
New York
$863K +$718K +29,220 +246%
Squarepoint
42
Squarepoint
New York
$825K +$148K +6,028 +18%
Marshall Wace
43
Marshall Wace
United Kingdom
$649K +$760K +30,898 New
BFM
44
Boothbay Fund Management
New York
$639K +$440K +17,902 +143%
Russell Investments Group
45
Russell Investments Group
United Kingdom
$574K -$82K -3,336 -11%
Swiss National Bank
46
Swiss National Bank
Switzerland
$558K +$22.1K +900 +4%
Bank of America
47
Bank of America
North Carolina
$494K +$543K +22,094 +1,506%
PPA
48
Parametric Portfolio Associates
Washington
$447K -$542K -22,060 -51%
CSS
49
Cubist Systematic Strategies
Connecticut
$442K +$518K +21,073 New
SO
50
STRS Ohio
Ohio
$382K

DCPH Hedge Fund Activity: Q4 2018 in Review

78 of the 4,488 institutional investors tracked by Wall St. Rank reported a position in Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) for Q4 2018, worth a combined $460M — down 44% from $822M a quarter earlier.

Sellers outnumbered buyers: 25 funds closed out of DCPH and 15 opened new positions — a net loss of 10 holders — while 19 trimmed existing stakes and 31 added.

The largest buyer was Millennium Management, adding an estimated $28.6M. The largest seller was Polar Capital, exiting entirely with an estimated $31.2M sold.

  • 78 institutional investors held Deciphera Pharmaceuticals, Inc. Common Stock (DCPH) as of Q4 2018, down from 88 in Q3 2018.
  • Funds reported $460M of Deciphera Pharmaceuticals, Inc. Common Stock stock for Q4 2018, down 44% quarter-over-quarter.
  • 15 funds opened new Deciphera Pharmaceuticals, Inc. Common Stock positions in Q4 2018 and 25 closed out, a net change of -10 holders.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock buyer in Q4 2018 was Millennium Management, an estimated $28.6M added.
  • The largest Deciphera Pharmaceuticals, Inc. Common Stock seller in Q4 2018 was Polar Capital, an estimated $31.2M sold.

Based on aggregated 13F filings for Q4 2018.